[State and perspectives of training of highly qualified surgeons (heads of departments)].

A. Rusanov,P. P. Alekseev,G. N. Zakharova,Iu Ia Gordeev,F. K. Kutushev,P. Volkov

VESTNIK KHIRURGII IMENI I.I.GREKOVA

Abstract:

What problem does this paper attempt to address?

[Noncompliance relevant variables in patients with onychomycosis].

I. Effendy,H. Kolczak,H. Friederich

1989-08-31

Wiener Medizinische Wochenschrift

Abstract:In a prospective clinical study we have investigated the relevant non-compliance variables with 96 patients affected by onychomycosis, who underwent a combined treatment of nail abrasion and application of a topical antifungal. The patients' non-compliance amounted to 24% of the complete group examined. Significantly this occurred more frequently with men (31.6%) than with women (12.8%), and also more frequently with older women than younger women. It occurred with 42% of the male and female pensioners and with 43% of the students. Furthermore, the group of non-compliance patients, in addition to their onychomycosis, frequently exhibited other illnesses requiring treatment in greater degree than the compliant patients. Additional rising variables, e.g. in the seriousness of the clinical outbreaks on the nails and the number of mycotic nails, did not contribute to an explanation of the differences in compliance behavior of the patients. By careful observation of the compliance factors in relation to specific illnesses, a more favorable set of conditions should be achieved in future for the improvement of patient behavior.
The ideological survey.

F. C. Thorne,V. Pishkin

DOI: https://doi.org/10.1002/1097-4679(196807)24:3<263::AID-JCLP2270240302>3.0.CO;2-I

1968-07-01

Journal of Clinical Psychology

Abstract:
Impact of Early Changes in Cardiac Damage Following Transcatheter Aortic Valve Implantation.

Yaoyao Zhou,Qifeng Zhu,Xinping Lin,Huajun Li,Zhaoxia Pu,Xianbao Liu,Jian'an Wang

DOI: https://doi.org/10.4244/eij-d-22-00817

2023-01-01

Abstract:BACKGROUNDThe staging classification of aortic stenosis (AS) which characterises the extent of cardiac damage has been validated in patients undergoing transcatheter aortic valve implantation (TAVI). Short-term changes in cardiac damage after TAVI and their association with long-term prognosis remain unknown.AIMSThis study aims to investigate the early evolution of cardiac damage after TAVI and the association of residual cardiac damage with clinical outcomes in TAVI recipients.METHODSAS patients undergoing TAVI were consecutively enrolled and classified into five stages of cardiac damage (0-4). Early change in cardiac damage was defined as any change of stage at 30 days (Δcardiac damage between baseline pre-TAVI and 30 days post-TAVI).RESULTSWithin 30 days post-TAVI, the baseline cardiac damage stage had changed in 22.2% of 644 TAVI recipients, accompanied by improvements in the degree of dyspnoea and left ventricular ejection fraction (LVEF). Two-year mortality was associated with residual cardiac damage within 30 days post-TAVI (hazard ratio [HR] 2.97, 95% confidence interval [CI]: 2.07-4.25; p<0.001). Compared to unchanged cardiac damage post-TAVI, further cardiac damage within 30 days was associated with a higher crude risk of 2-year mortality (HR 22.04, 95% CI: 9.87-49.20; p<0.001). Cardiac deterioration within 30 days post-TAVI was an independent risk factor for 2-year mortality (HR 19.564, 95% CI: 8.047-47.565; p<0.001).CONCLUSIONSThis investigation provided insight into the early evolution of cardiac damage in TAVI recipients and confirmed the predictive value of both residual and early changes in cardiac damage post-TAVI. Cardiac deterioration within 30 days is associated with poor clinical prognosis.
The impact of extra-valvular cardiac damage on mid-term clinical outcome following transcatheter aortic valve replacement in patients with severe aortic stenosis

Costanza Pellegrini,Charlotte Duesmann,Tobias Rheude,Amelie Berg,Hector A. Alvarez-Covarrubias,Teresa Trenkwalder,N. Patrick Mayr,Friederike Schürmann,Philipp Nicol,Erion Xhepa,Michael Joner

DOI: https://doi.org/10.3389/fcvm.2022.1039208

IF: 3.6

2022-12-02

Frontiers in Cardiovascular Medicine

Abstract:Aims: To quantify extra-valvular cardiac damage associated with severe aortic valve stenosis (AS), a novel staging model was proposed. This study aimed to validate this model in patients undergoing transcatheter aortic valve replacement (TAVR) as well as to assess its prognostic impact. Methods and results: Based on echocardiographic findings, the following stages were applied: isolated AS (stage 0), left ventricular (LV) damage (stage 1), left atrial or mitral valve damage (stage 2), pulmonary hypertension or tricuspid regurgitation (stage 3), or right ventricular dysfunction (stage 4). The primary endpoint was 2-year all-cause mortality. The distribution across stages was 0.8% at stage 0, 7.5% at stage 1, 63.3% at stage 2, 18.3% at stage 3, and 10.1% at stage 4. All-cause mortality increased at all stages 1–4 (12.1%, 18.2%, 26.6%, and 28.2%; p = 0.023). In the multivariate model, the stage of cardiac damage, age, New York Heart Association (NYHA) class III/IV, peripheral artery disease, and previous pacemaker were independent predictors of the primary endpoint. Conclusions: Patients treated for severe AS show a high prevalence of extra-valvular cardiac damage. An increase in stage is associated with higher 2-year all-cause mortality. The application of this staging model may add value to current treatment algorithms.

cardiac & cardiovascular systems
891 EARLY EVOLUTION OF CARDIAC DAMAGE STAGING FOLLOWING TRANSCATHETER AORTIC VALVE REPLACEMENT: PREVALENCE, CLINICAL PATTERNS AND PROGNOSTIC SIGNIFICANCE

Luca Scudeler,Guglielmo Gallone,Francesco Bruno,Antonio Signorini,Riccardo Gorla,Francesco Melillo,Maurizio Tusa,Matteo Montorfano,Pasquale Leone,Paolo Cimaglia,Maria Concetta Pastore,Giovanni Benfari,Federico Landra,Anna Franzone,Renato Bragato,Paolo Spiringhetti,Alessandro Andreis,Michele Trichilo,Giuseppe Patti,Matteo Cameli,Fabrizio D´ascenzo,Gaetano Maria De Ferrari

DOI: https://doi.org/10.1093/eurheartjsupp/suac121.749

2022-12-14

European Heart Journal Supplements

Abstract:Abstract Background The early evolution of extravalvular cardiac damage following transcatheter aortic valve replacement (TAVR) as assessed by a previous validated score system remains unstudied. We sought to assess the patterns of early cardiac damage change among patients with severe aortic stenosis (AS) undergoing TAVR and its prognostic implications. Methods The RECOVERY-TAVR is a multi-center, international retrospective registry including all consecutive patients undergoing TAVR in thirteen high-volume centers. All the enrolled patients with available paired echocardiography assessment pre- and post TAVR were included in this sub-analysis. Patients were categorized according to the extension of cardiac damage based on a previous published and validated classification (stage 0, no damage; stage 1, left ventricular damage; stage 2, left atrial or mitral valve damage; stage 3, pulmonary vasculature or tricuspid valve damage; and stage 4, right ventricular damage). The primary endpoint was a composite of all-cause mortality or first heart failure hospitalization at 1 year. The association of cardiac damage stage evaluated prior and following TAVR along with the staging evolution was assessed with multivariate Cox regression model (that include hemoglobin, NYHA class and max aortic valve gradient) for the primary outcome. Results Of 1331 Patients included in the RECOVERY-TAVR registry with a full echocardiographic pre-TAVR assessment, 892 patients with available paired echocardiography exams were finally included in this analysis (pre-TAVR assessment: median 8 days prior to TAVR; post-TAVR assessment: median 7 days post-TAVR). 63 (7.1%) had stage 0/1, 433 (48.2%) had stage 2, 235 (26.3%) had stage 3 and 161 (18%) had stage 4 myocardial damage. Pre-TAVR myocardial damage staging was associated with the primary outcome (Adj-HR for myocardial stage increase: HR 1.40, 95% CI 1.01–1.93). Following TAVR 274 (30.7%) patients experienced myocardial damage improvement and 161 (18.1%) myocardial damage worsening. Post-TAVR myocardial damage staging was more strongly associated with the primary outcome (HR 1.55, 95%CI 1.14–2.10) as compared to pre-TAVR assessment. Male Sex (p = 0.044) and post-procedural permanent pacemaker implantation (p = 0.044) was associated with myocardial damage worsening, while the use of a balloon-expandable valve (p = 0.011) was associated with myocardial damage improvement. Early myocardial damage worsening (HR 1.89, 95%CI 1.12–3.21), but not early myocardial damage improvement (HR 0.86, 95%CI 0.54–1.37) was associated with the primary outcome. Conclusion In patients undergoing TAVR, the extent of extravalvular cardiac damage prior to and early after TAVR has an independent prognostic value while early myocardial damage worsening following TAVR portends a poor prognosis. Whether strategies to improve procedural success and treatments addressing extravalvular myocardial damage early following TAVR may improve outcomes has to be prospectively assessed.

cardiac & cardiovascular systems
Early evolution of cardiac damage staging following transcatheter aortic valve replacement: prevalence, clinical patterns and prognostic significance

L Scudeler,G Gallone,F Bruno,A Signorini,R Gorla,F Melillo,P Leone,P Cimaglia,M C Pastore,G Benfari,F Landra,A Andreis,F D'ascenzo,G M De Ferrari

DOI: https://doi.org/10.1093/ehjci/jead119.261

2023-06-01

European Heart Journal - Cardiovascular Imaging

Abstract:Abstract Funding Acknowledgements Type of funding sources: None. Background The early evolution of extravalvular cardiac damage following transcatheter aortic valve replacement (TAVR) as assessed by a previous validated score system remains unstudied. We sought to assess the patterns of early cardiac damage change among patients with severe aortic stenosis (AS) undergoing TAVR and its prognostic implications. Methods The RECOVERY-TAVR is a multi-center, international retrospective registry including all consecutive patients undergoing TAVR in thirteen high-volume centers. All the enrolled patients with available paired echocardiography assessment pre- and post TAVR were included in this sub-analysis. Patients were categorized according to the extension of cardiac damage based on a previous published and validated classification (stage 0, no damage; stage 1, left ventricular damage; stage 2, left atrial or mitral valve damage; stage 3, pulmonary vasculature or tricuspid valve damage; and stage 4, right ventricular damage). The primary endpoint was a composite of all-cause mortality or first heart failure hospitalization at 1 year. The association of cardiac damage stage evaluated prior and following TAVR along with the staging evolution was assessed with multivariate Cox regression model (that include hemoglobin, NYHA class and max aortic valve gradient) for the primary outcome. Results Of 1331 Patients included in the RECOVERY-TAVR registry with a full echocardiographic pre-TAVR assessment, 892 patients with available paired echocardiography exams were finally included in this analysis (pre-TAVR assessment: median 8 days prior to TAVR; post-TAVR assessment: median 7 days post-TAVR). 63 (7.1%) had stage 0/1, 433 (48.2%) had stage 2, 235 (26.3%) had stage 3 and 161 (18%) had stage 4 myocardial damage. Pre-TAVR myocardial damage staging was associated with the primary outcome (Adj-HR for myocardial stage increase: HR 1.40, 95% CI 1.01 – 1.93). Following TAVR 274 (30.7%) patients experienced myocardial damage improvement and 161 (18.1%) myocardial damage worsening. Post-TAVR myocardial damage staging was more strongly associated with the primary outcome (HR 1.55, 95%CI 1.14 – 2.10) as compared to pre-TAVR assessment. Male Sex (p = 0.044) and post-procedural permanent pacemaker implantation (p = 0.044) was associated with myocardial damage worsening. Early myocardial damage worsening (HR 1.89, 95%CI 1.12 – 3.21), but not early myocardial damage improvement (HR 0.86, 95%CI 0.54 – 1.37) was associated with the primary outcome. Conclusion In patients undergoing TAVR, the extent of extravalvular cardiac damage prior to and early after TAVR has an independent prognostic value while early myocardial damage worsening following TAVR portends a poor prognosis. Whether strategies to improve procedural success and treatments addressing extravalvular myocardial damage early following TAVR may improve outcomes has to be prospectively assessed.

radiology, nuclear medicine & medical imaging,cardiac & cardiovascular systems
Extent of cardiac damage and hospitalization burden in patients undergoing transcatheter aortic valve replacement

Pernille Steen Bække,Laurits Lykkeskov Gran,Troels Højsgaard Jørgensen,Angie Ghattas,Emil Fosbøl,Lars Sondergaard,Ole De Backer

DOI: https://doi.org/10.1002/ccd.31015

IF: 2.3

2024-04-03

Catheterization and Cardiovascular Interventions

Abstract:Background Cardiac damage has gained increasing attention as a valid prognostic marker of mortality after transcatheter aortic valve replacement (TAVR). However, studies investigating the possible association between cardiac damage and hospitalization burden in TAVR patients are lacking. Aims This study aimed to investigate the impact of baseline cardiac damage on the hospitalization burden before, during, and after TAVR in an all‐comers population. Methods All consecutive patients who underwent TAVR between 2016 and 2020 were included. Electronic medical records of all patients were examined to validate cardiovascular (CV) and heart failure (HF) related hospitalizations from 6 months before to 1 year after TAVR. Baseline cardiac damage was defined according to the staging classification by Généreux et al. Results Among 1397 TAVR patients, 94 (6.7%) had stage 0, 368 (26.4%) stage 1, 736 (52.7%) stage 2, 115 (8.2%) stage 3, and 84 (6.0%) stage 4 cardiac damage. Patients with more advanced cardiac damage at baseline had more HF hospitalizations within 6 months before TAVR (p

cardiac & cardiovascular systems
Extent of Cardiac Damage and Mortality in Patients Undergoing Transcatheter Aortic Valve Implantation

Marisa Avvedimento,Anna Franzone,Attilio Leone,Raffaele Piccolo,Domenico Simone Castiello,Federica Ilardi,Andrea Mariani,Roberta Esposito,Cristina Iapicca,Domenico Angellotti,Maria Scalamogna,Ciro Santoro,Luigi Di Serafino,Plinio Cirillo,Giovanni Esposito

DOI: https://doi.org/10.3390/jcm10194563

IF: 3.9

2021-09-30

Journal of Clinical Medicine

Abstract:(1) Aims: We sought to assess the impact of the extent of cardiac damage on survival among real-world patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve implantation (TAVI). (2) Methods: A staging classification was applied to 262 patients from the EffecTAVI Registry at baseline and re-assessed within 30-days after TAVI. The primary endpoint of the study was all-cause mortality at 1-year. Secondary endpoints included cerebrovascular accident, myocardial infarction, permanent pacemaker implantation, endocarditis, and re-hospitalization for all causes. (3) Results: At baseline, 23 (8.7%) patients were in Stage 0/1 (no cardiac damage/left ventricular damage), 106 (40.4%) in Stage 2 (left atrial or mitral valve damage), 59 (22.5%) in Stage 3 (pulmonary vasculature or tricuspid valve damage) and 74 (28.3%) in Stage 4 (right ventricular damage). At 30-days after TAVI, a lower prevalence of advanced stages of cardiac damage than baseline, mainly driven by a significant improvement in left ventricular diastolic parameters and right ventricular function, was reported. At 1-year, a stepwise increase in mortality rates was observed according to staging at baseline: 4.3% in Stage 0/1, 6.6% in Stage 2, 18.6% in Stage 3 and 21.6% in Stage 4 (p = 0.08). No differences were found in secondary endpoints. (4) Conclusions: TAVI has an early beneficial impact on the left ventricular diastolic and right ventricular function. However, the extent of cardiac damage at baseline significantly affects the risk of mortality at 1-year after the procedure.

medicine, general & internal
The Impact of Severe Ventricular Remodeling on Quality-of-Life Outcomes after Transcatheter Aortic Valve Replacement

Pavan Reddy,Ilan Merdler,Cheng Zhang,Matteo Cellamare,Itsik Ben-Dor,Lowell F. Satler,Toby Rogers,William S. Weintraub,Ron Waksman

DOI: https://doi.org/10.1101/2023.04.28.23289291

2023-04-30

MedRxiv

Abstract:Background Among patients with aortic stenosis, severe ventricular remodeling can limit the augmentation of flow with exertion, even after valve intervention. While long-term mortality risk has been shown be elevated in this patient population, the effect on quality of life (QoL) improvement has not been studied. Our objective was to determine the effect of severe ventricular remodeling on QoL outcomes after transcatheter aortic valve replacement (TAVR). Methods All patients undergoing TAVR from 2011-2021 at our institution were included. Groups were divided according to guideline-recommended cutoffs for left ventricular (LV) wall thickness. Normal or mild wall thickness was designated as non-remodeled (NR) and moderate/severe wall thickness defined the remodeled group (REM). The Kansas City Cardiomyopathy Questionnaire (KCCQ) was utilized to assess QoL and the primary outcome was KCCQ change <5 from baseline to 30 days and 1 year. Results We analyzed 679 patients (NR: N=389, REM: N=290). Baseline KCCQ overall score [OS] trended higher in the NR group (60.1 vs. 56.6, p=0.053). Echocardiographic baseline differed between NR and REM by septal thickness (1.12 cm vs. 1.44 cm, p<0.001), posterior wall thickness (1.08 cm vs. 1.33 cm, p<0.001), and LV internal diastolic diameter (4.34 cm vs. 4.19 cm, p=0.006). The primary outcome was similar between NR and REM at 30 days (31.6% vs. 28.6%, p=0.449) and at 1 year (27.7% vs. 21.5%, p=0.217). NR and REM experienced similar proportions of worsening or no change, small, moderate, and large improvements in KCCQ score (<5, 5-10, 10-19, [≥]20, respectively). Both groups experienced similar domain score changes and NYHA improvement. At one year, NR demonstrated greater reduction in 5MWT time compared to REM (-1.98 s vs. -0.2 s, p=0.028). A subgroup analysis of REM patients did not reveal interaction with cavity size, stroke volume, mitral regurgitation, E/A ratio, valvulo-arterial impedance, or hyperdynamic ejection fraction. Conclusions Patients with severe ventricular remodeling and aortic stenosis have similar QoL changes after intervention compared to patients without significant remodeling. Findings from this study support aortic valve intervention irrespective of ventricular remodeling.
Paravalvular regurgitation after transcatheter aortic valve replacement in intermediate-risk patients: a pooled PARTNER 2 study

Katherine H Chau,Shmuel Chen,Aaron Crowley,Bjorn Redfors,Ditian Li,Rebecca T Hahn,Pamela S Douglas,Maria C Alu,Matthew T Finn,Susheel Kodali,Wael A Jaber,Leonardo Rodriguez,Vinod H Thourani,Philippe Pibarot,Martin B Leon

DOI: https://doi.org/10.4244/EIJ-D-20-01293

2022-01-28

EuroIntervention

Abstract:Background: Moderate or worse paravalvular regurgitation (PVR) post transcatheter aortic valve replacement (TAVR) is associated with increased mortality. The mechanisms by which this occurs are not fully understood. Aims: The aim of this study was to determine the mechanism by which PVR leads to worse outcomes. Methods: A total of 1,974 intermediate-risk patients who received TAVR in the PARTNER 2 trial and registries were grouped by PVR severity. Clinical and echocardiographic outcomes were compared. Results: Overall 1,176 (60%) patients had none/trace, 680 (34%) had mild, and 118 (6%) had ≥moderate PVR. At two years, ≥moderate PVR patients had increased risks of all-cause (HR 2.33 [1.41-3.85], p-value=0.001) and cardiovascular death (HR 3.30 [1.74-6.28], p-value <0.001), rehospitalisation (HR 2.68 [1.57-4.58], p-value <0.001), and reintervention (HR 14.72 [3.13-69.32], p-value <0.001). Moderate or worse PVR was associated with larger increases in left ventricular (LV) end-diastolic and systolic dimensions and volumes, LV mass indices, and reductions in LV ejection fractions (LVEFs) from 30 days to two years. Mild PVR was not associated with worse outcomes. Adjusting for LV dimensions and LVEF from the one-year echocardiogram, patients with ≥moderate PVR still had an increased risk of all-cause death or rehospitalisation at two years (HR 2.84 [1.25-5.78], p-value=0.009). Conclusions: Moderate or worse PVR, but not mild PVR, is associated with an increased risk of all-cause and cardiovascular death, rehospitalisation, and reintervention at two years. Moderate or worse PVR is also associated with adverse LV remodelling, which partially mediates how ≥moderate PVR leads to worse outcomes. These results provide dual insights on the deleterious impact of ≥moderate PVR and the contributing mechanisms of poor clinical outcomes.
Patient-Prosthesis Mismatch After Surgical Aortic Valve Replacement: Analysis of the PARTNER Trials

Vinod H Thourani,Amr E Abbas,Julien Ternacle,Rebecca T Hahn,Raj Makkar,Susheel K Kodali,Isaac George,Samir Kapadia,Lars G Svensson,Wilson Y Szeto,Howard C Herrmann,Gorav Ailawadi,Jonathon Leipsic,Philipp Blanke,John Webb,Wael A Jaber,Mark Russo,S Chris Malaisrie,Pradeep Yadav,Marie-Annick Clavel,Omar K Khalique,Neil J Weissman,Pamela Douglas,Jeroen Bax,Abdellaziz Dahou,Ke Xu,Vinayak Bapat,Maria C Alu,Martin B Leon,Michael J Mack,Philippe Pibarot,Vinod H. Thourani,Amr E. Abbas,Rebecca T. Hahn,Susheel K. Kodali,Lars G. Svensson,Wilson Y. Szeto,Howard C. Herrmann,Wael A. Jaber,S. Chris Malaisrie,Omar K. Khalique,Neil J. Weissman,Maria C. Alu,Martin B. Leon,Michael J. Mack

DOI: https://doi.org/10.1016/j.athoracsur.2024.01.023

IF: 5.113

2024-02-01

The Annals of Thoracic Surgery

Abstract:BACKGROUND: Our objective was to compare the impact of patient-prosthesis mismatch (PPM) for 2 years after surgical aortic valve replacement within the prospective, randomized Placement of Aortic Transcatheter Valves (PARTNER) trials.METHODS: Surgical aortic valve replacement patients from the PARTNER 1, 2, and 3 trials were included. PPM was classified as moderate (indexed effective orifice area ≤0.85 cm2/m2) or severe (indexed effective orifice area ≤0.65 cm2/m2). The primary endpoint was the composite of all-cause death and heart failure rehospitalization at 2 years.RESULTS: By the predicted PPM method (PPMP), 59.1% had no PPM, 38.8% moderate PPM, and 2.1% severe PPM; whereas by the measured PPM method (PPMM), 42.4% had no PPM, 36.0% moderate, and 21.6% severe. Patients with no PPMP (23.6%) had a lower rate of the primary endpoint compared with patients with moderate (28.2%, P = .03) or severe PPMP (38.8%, P = .02). Using the PPMM method, there was no difference between the no (17.7%) and moderate PPMM groups (21.1%) in the primary outcome (P = .16). However, those with no PPMM or moderate PPMM were improved compared with severe PPMM (27.4%, P < .001 and P = .02, respectively).CONCLUSIONS: Severe PPM analyzed by PPMP was only 2.1% for surgical aortic valve replacement patients. The PPMM method overestimated the incidence of severe PPM relative to PPMP, but was also associated with worse outcome. There was higher all-cause mortality in patients with severe PPM, thus surgical techniques to minimize PPM remain critical.

surgery,cardiac & cardiovascular systems,respiratory system
Outcome of aortic stenosis according to invasive cardiac damage staging after transcatheter aortic valve replacement

Jury Schewel,Karl-Heinz Kuck,Christian Frerker,Tobias Schmidt,Dimitry Schewel

DOI: https://doi.org/10.1007/s00392-021-01835-w

IF: 6.138

2021-03-20

Clinical Research in Cardiology

Abstract:<h3 class="a-plus-plus">Background</h3>In recent studies, a 5-stage cardiac damage classification in severe aortic stenosis (AS) based on echocardiographic parameters has shown to provide predictive value regarding clinical outcome. The objective of this study was to investigate the prognostic impact of a cardiac damage classification based on invasive hemodynamics in patients with AS undergoing transcatheter aortic valve replacement (TAVR).<h3 class="a-plus-plus">Methods</h3>A total of 1400 patients with symptomatic AS and full invasive hemodynamic assessment before TAVR were included. Patients were categorized according to their cardiac damage stage into five groups that are defined as: stage 0, no cardiac damage; stage 1, left ventricular damage; stage 2, left atrial and/or mitral valve damage; stage 3, pulmonary vasculature and/or tricuspid valve damage; stage 4, right ventricular damage.<h3 class="a-plus-plus">Results</h3>9.9% patients were classified as stage 0, 23.6% as stage 1, the majority of patients as stage 2 (33.5%), 23.1% as stage 3 and 10% as stage 4. One- and 4-year mortality were 10.1%/29.5% in stage 0, 16.1%/60.6% in stage 1, 17.3%/39.4% in stage 2, 22%/54.6% in stage 3, 27.1%/62.2% in stage 4 (p = 0.001/p < 0.001). The extent of cardiac damage was independently associated with increased mortality after TAVR (HR 1.16 per each increment in stage, 95% confidence interval 1.03–1.18; p = 0.018).<h3 class="a-plus-plus">Conclusions</h3>Cardiac damage staging in severe AS patients based on invasive hemodynamics appears to show strong association between the extent of cardiac damage and post-TAVR mortality. This staging classification provides predictive value and may improve risk stratification, therapy management and decision-making in patients with AS.<h3 class="a-plus-plus">Graphic abstract</h3><caption class="a-plus-plus caption language-en lang-en"> Invasive Staging Classification of Cardiac Damage in Severe Symptomatic Aortic Stenosis has an Impact on Outcome after TAVR. (Top) Invasive staging criteria for cardiac damage in five stages using left ventricular end-diastolic pressure (LVEDP) for stage 1 (red), post-capillary wedge pressure (PCWP) for stage 2 (green), systolic pulmonary artery pressure (SPAP) for stage 3 (purple) and right atrial pressure (RAP) for stage 4 (yellow). The cake chart shows the distribution of the different stage in the whole cohort. (Bottom) Survival Analyses According to Stage of Cardiac Damage after Transcatheter Aortic Valve Replacement using Invasive Criteria. Kaplan-Meier plots comparing overall (left) and cardiovascular (right) 4-year survival showing with the more advancing stage a higher mortality rate </caption>

cardiac & cardiovascular systems
Outcomes of SAPIEN 3 Transcatheter Aortic Valve Replacement Compared With Surgical Valve Replacement in Intermediate-Risk Patients

Mahesh V Madhavan,Susheel K Kodali,Vinod H Thourani,Raj Makkar,Michael J Mack,Samir Kapadia,John G Webb,David J Cohen,Howard C Herrmann,Mathew Williams,Kevin Greason,Philippe Pibarot,Rebecca T Hahn,Wael Jaber,Ke Xu,Maria Alu,Craig R Smith,Martin B Leon

DOI: https://doi.org/10.1016/j.jacc.2023.04.049

2023-07-11

Abstract:Background: Previous studies demonstrated transcatheter aortic valve replacement (TAVR) with an earlier generation balloon-expandable valve to be noninferior to surgical aortic valve replacement (SAVR) for death and disabling stroke in intermediate-risk patients with symptomatic, severe aortic stenosis at 5 years. However, limited long-term data are available with the more contemporary SAPIEN 3 (S3) bioprosthesis. Objectives: The aim of this study was to compare 5-year risk-adjusted outcomes in intermediate-risk patients undergoing S3 TAVR vs SAVR. Methods: Propensity score matching was performed to account for baseline differences in intermediate-risk patients undergoing S3 TAVR in the PARTNER 2 (Placement of Aortic Transcatheter Valves) S3 single-arm study and SAVR in the PARTNER 2A randomized clinical trial. The primary composite endpoint consisted of 5-year all-cause death and disabling stroke. Results: A total of 783 matched pairs of intermediate-risk patients with severe aortic stenosis were studied. There were no differences in the primary endpoint between S3 TAVR and SAVR at 5 years (40.2% vs 42.7%; HR: 0.87; 95% CI: 0.74-1.03; P = 0.10). The incidence of mild or greater paravalvular regurgitation was more common after S3 TAVR. There were no differences in structural valve deterioration-related stage 2 and 3 hemodynamic valve deterioration or bioprosthetic valve failure. Conclusions: In this propensity-matched analysis of intermediate-risk patients, 5-year rates of death and disabling stroke were similar between S3 TAVR and SAVR. Rates of structural valve deterioration-related hemodynamic valve deterioration were similar, but paravalvular regurgitation was more common after S3 TAVR. Longer-term follow-up is needed to further evaluate differences in late adverse clinical events and bioprosthetic valve durability. (PII S3i [PARTNER II Trial: Placement of Aortic Transcatheter Valves II - S3 Intermediate], NCT03222128; PII A (PARTNER II Trial: Placement of Aortic Transcatheter Valves II - XT Intermediate and High Risk], NCT01314313).
Quality of Life 5 Years Following Transfemoral TAVR or SAVR in Intermediate Risk Patients

Neal S. Kleiman,Nicolas M. Van Mieghem,Michael J. Reardon,Hemal Gada,Mubashir Mumtaz,Peter Skov Olsen,John Heiser,William Merhi,Stanley Chetcuti,G. Michael Deeb,Atul Chawla,Bob Kiaii,Patrick Teefy,Michael W.A. Chu,Steven J. Yakubov,Stephan Windecker,Andrew D. Althouse,Suzanne J. Baron

DOI: https://doi.org/10.1016/j.jcin.2024.02.014

IF: 11.075

2024-04-24

JACC Cardiovascular Interventions

Abstract:Background Symptomatic patients with severe aortic stenosis (AS) at high risk for surgical aortic valve replacement (SAVR) sustain comparable improvements in health status over 5 years after transcatheter aortic valve replacement (TAVR) or SAVR. Whether a similar long-term benefit is observed among intermediate-risk AS patients is unknown. Objectives The purpose of this study was to assess health status outcomes through 5 years in intermediate risk patients treated with a self-expanding TAVR prosthesis or SAVR using data from the SURTAVI (Surgical Replacement and Transcatheter Aortic Valve Implantation) trial. Methods Intermediate-risk patients randomized to transfemoral TAVR or SAVR in the SURTAVI trial had disease-specific health status assessed at baseline, 30 days, and annually to 5 years using the Kansas City Cardiomyopathy Questionnaire (KCCQ). Health status was compared between groups using fixed effects repeated measures modelling. Results Of the 1,584 patients (TAVR, n = 805; SAVR, n = 779) included in the analysis, health status improved more rapidly after TAVR compared with SAVR. However, by 1 year, both groups experienced large health status benefits (mean change in KCCQ-Overall Summary Score (KCCQ-OS) from baseline: TAVR: 20.5 ± 22.4; SAVR: 20.5 ± 22.2). This benefit was sustained, albeit modestly attenuated, at 5 years (mean change in KCCQ-OS from baseline: TAVR: 15.4 ± 25.1; SAVR: 14.3 ± 24.2). There were no significant differences in health status between the cohorts at 1 year or beyond. Similar findings were observed in the KCCQ subscales, although a substantial attenuation of benefit was noted in the physical limitation subscale over time in both groups. Conclusions In intermediate-risk AS patients, both transfemoral TAVR and SAVR resulted in comparable and durable health status benefits to 5 years. Further research is necessary to elucidate the mechanisms for the small decline in health status noted at 5 years compared with 1 year in both groups. (Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement [SURTAVI]; NCT01586910 )

cardiac & cardiovascular systems
[A case of mild pulmonary tuberculosis complicated with the syndrome of inappropriate antidiuretic hormone secretion which caused impaired consciousness].

T. Minami,K. Wakamatsu,H. Kumazoe,N. Nagata,A. Kajiki,Y. Kitahara

2011-08-01

Abstract:An 81-year-old woman was admitted to our hospital for hyponatremia and impaired consciousness after unsuccessful antibiotic treatment for pneumonia-like symptoms by a previous doctor. A chest X-ray film revealed unilateral infiltration. Mycobacterium tuberculosis was detected on a sputum smear and pulmonary tuberculosis was diagnosed. Based on the diagnostic criteria, we believed that her hyponatremia a consequence of syndrome of inappropriate antidiuretic hormone secretion (SIADH) as a complication of pulmonary tuberculosis. Sodium loading and water restriction quickly improved her serum sodium level and impaired consciousness. Anti-tuberculosis therapy reduced the abnormal shadows noted on chest X-ray films, and the sputum smear became negative for Mycobacterium tuberculosis. Her serum sodium level remained normal after the discontinuation of sodium loading. Previous reports have associated SIADH with severe types of tuberculosis such as miliary tuberculosis, tuberculosis meningitis, and pulmonary tuberculosis with massive bacterial excretion. However, this complication can also occur in mild tuberculosis, as in this case, thus SIADH should also be considered in mild cases of tuberculosis.
Effect of aortic valve replacement on myocardial perfusion and exercise capacity in patients with severe aortic stenosis

Saadia Aslam,Abhishek Dattani,Aseel Alfuhied,Gaurav S. Gulsin,Jayanth R. Arnold,Christopher D. Steadman,Michael Jerosch-Herold,Hui Xue,Peter Kellman,Gerry P. McCann,Anvesha Singh

DOI: https://doi.org/10.1038/s41598-024-72480-2

IF: 4.6

2024-09-16

Scientific Reports

Abstract:Aortic valve replacement (AVR) leads to reverse cardiac remodeling in patients with aortic stenosis (AS). The aim of this secondary pooled analysis was to assess the degree and determinants of changes in myocardial perfusion post AVR, and its link with exercise capacity, in patients with severe AS. A total of 68 patients underwent same-day echocardiography and cardiac magnetic resonance imaging with adenosine stress pre and 6–12 months post-AVR. Of these, 50 had matched perfusion data available (age 67 ± 8 years, 86% male, aortic valve peak velocity 4.38 ± 0.63 m/s, aortic valve area index 0.45 ± 0.13cm 2 /m 2 ). A subgroup of 34 patients underwent a symptom-limited cardiopulmonary exercise test (CPET) to assess maximal exercise capacity (peak VO 2 ). Baseline and post-AVR parameters were compared and linear regression was used to determine associations between baseline variables and change in myocardial perfusion and exercise capacity. Following AVR, stress myocardial blood flow (MBF) increased from 1.56 ± 0.52 mL/min/g to 1.80 ± 0.62 mL/min/g ( p < 0.001), with a corresponding 15% increase in myocardial perfusion reserve (MPR) (2.04 ± 0.57 to 2.34 ± 0.68; p = 0.004). Increasing severity of AS, presence of late gadolinium enhancement, lower baseline stress MBF and MPR were associated with a greater improvement in MPR post-AVR. On multivariable analysis low baseline MPR was independently associated with increased MPR post-AVR. There was no significant change in peak VO 2 post-AVR, but a significant increase in exercise duration. Change in MPR was associated with change in peak VO 2 post AVR (r = 0.346, p = 0.045). Those with the most impaired stress MBF and MPR at baseline demonstrate the greatest improvements in these parameters following AVR and the magnitude of change in MPR correlated with improvement in peak VO 2 , the gold standard measure of aerobic exercise capacity.

multidisciplinary sciences
Association between trajectories in cardiac damage and clinical outcomes after transcatheter aortic valve replacement

Yaoyao Zhou,Xinping Lin,Qifeng Zhu,Huajun Li,Zhaoxia Pu,Xianbao Liu,Jian'an Wang

DOI: https://doi.org/10.1016/j.ijcard.2023.05.017

2023-09-01

Abstract:Background: There is little evidence of evolution in cardiac damage after transcatheter aortic valve replacement (TAVR) in aortic stenosis (AS) patients. Less is known about the prognostic value and potential utility of different cardiac damage trajectories following TAVR. Objectives: This study aims to investigate the cardiac damage trajectories following TAVR and explore their association with subsequent clinical outcomes. Methods: AS patients undergoing TAVR were enrolled and classified into five cardiac damage stages (0-4) based on the echocardiographic staging classification retrospectively. They were further grouped into early stage (stage 0-2) and advanced stage (stage 3-4). The cardiac damage trajectories in TAVR recipients were evaluated according to their trend between baseline and 30 days after TAVR. Results: A total of 644 TAVR recipients were enrolled, with four distinct trajectories identified. Compared to patients with early-early trajectory, patients with early-advanced trajectory were at 30-fold risk of all-cause death (HR 30.99, 95% CI 13.80-69.56; p < 0.001). In multivariable analyses, early-advanced trajectory was associated with higher 2-year all-cause death (HR 24.08, 95% CI 9.07-63.90; p < 0.001), cardiac death (HR 19.34, 95% CI 3.06-122.34; p < 0.05), and cardiac rehospitalization (HR 4.19, 95% CI 1.49-11.76; p < 0.05) after TAVR. Conclusions: This investigation provided insight into four cardiac damage trajectories in TAVR recipients and confirmed the prognostic value of distinct trajectories. Early-advanced trajectory was associated with poor clinical prognosis following TAVR.
Impact of age on health status after TAVI or SAVR in low risk patients with severe aortic stenosis: results from the PARTNER 3 Trial

M I Brener,X Yu,S J Baron,M Mack,V Thourani,S Kodali,R Makkar,P Pibarot,R T Hahn,M Leon,D J Cohen

DOI: https://doi.org/10.1093/eurheartj/ehae666.2454

IF: 39.3

2024-10-29

European Heart Journal

Abstract:Background Transcatheter aortic valve implantation (TAVI) results in similar 5-year survival and quality of life compared with surgical aortic valve replacement (SAVR) in patients with severe aortic stenosis (AS) and low surgical risk. Whether participants' age at the time of intervention influences the health status benefit of TAVI vs. SAVR is unknown. Purpose To assess the relationship between age and both the short- and long-term health status outcomes of TAVI vs. SAVR among patients enrolled in the PARTNER 3 trial. Methods We used data from the PARTNER 3 randomized trial to compare health status outcomes between TAVI and SAVR, stratified by age ( 75 at 5-year follow-up without a decline of >10 points from baseline. Results Between March 2016 and October 2017, 1000 low-risk patients with severe AS were randomized in a 1:1 fashion to transfemoral TAVR using the balloon-expandable Sapien 3 valve or surgery in the PARTNER 3 trial. Among patients who underwent TAVI or SAVR (and had baseline health status available; TAVI: 494, SAVR: 449), 228 (24%) were <70, 284 (30%) were 70-74, 287 (31%) were 75-79, and 144 (15%) were ≥80 years old. Baseline health status was similar between the TAVI and SAVR groups as well as across age strata. At 30-day follow-up, health status was substantially better with TAVI than SAVR with similar differences across age strata (mean difference 13-18 points; Figure 1). At all other timepoints, there were no significant differences between TAVI and SAVR in any age group. The proportion of TAVI patients with an excellent outcome at 5-year follow-up ranged from 86% in the youngest subgroup to 73% in the oldest subgroup, with no significant differences compared with SAVR. Conclusions Among patients with severe AS at low surgical risk, TAVI using the SAPIEN 3 balloon-expandable valve resulted in substantially better health status in the early post-procedure period compared with SAVR across all age strata. Beyond the early recovery period, intermediate- and longer-term health status outcomes were similar with TAVI and SAVR, with no evidence of heterogeneity by age. Although longer term follow-up is necessary (and ongoing), these 5-year outcomes suggest that over the age range included in the PARTNER 3 trial, age alone should not play a dominant role in determining treatment recommendations for patients with severe AS.Health status by treatment and age group

cardiac & cardiovascular systems
Impact of pulmonary hypertension on short-term outcomes in patients undergoing surgical aortic valve replacement for severe aortic valve stenosis

Borko Ivanov,Ihor Krasivskyi,Friedrich Förster,Christopher Gaisendrees,Ahmed Elderia,Clara Großmann,Mariya Mihaylova,Ilija Djordjevic,Kaveh Eghbalzadeh,Anton Sabashnikov,Elmar Kuhn,Antje-Christin Deppe,Parwis Baradaran Rahmanian,Navid Mader,Stephen Gerfer,Thorsten Wahlers

DOI: https://doi.org/10.1177/02676591241227883

2024-01-14

Perfusion

Abstract:Perfusion, Ahead of Print. ObjectivesIn patients with left heart disease and severe aortic stenosis (AS), pulmonary hypertension (PH) is a common comorbidity and predictor of poor prognosis. Untreated AS aggravates PH leading to an increased right ventricular afterload and, in line to right ventricular dysfunction. The surgical benefit of aortic valve replacement (AVR) in elderly patients with severe AS and PH could be limited due to the multiple comorbidities and poor outcomes. Therefore, we purposed to investigate the impact of PH on short-term outcomes in patients with moderate to severe AS who underwent surgical AVR in our heart center.MethodsIn this study we retrospectively analyzed a cohort of 99 patients with severe secondary post-capillary PH who underwent surgical AVR (AVR + PH group) at our heart center between 2010 and 2021 with a regard to perioperative outcomes. In order to investigate the impact of PH on short-term outcomes, the control group of 99 patients without pulmonary hypertension who underwent surgical AVR (AVR group) at our heart center with similar risk profile was accordingly analyzed regarding pre-, intra- and postoperative data.ResultsAtrial fibrillation occurred significantly more often (p = .013) in patients who suffered from PH undergoing AVR. In addition, the risk for cardiac surgery (EUROSCORE II) was significantly higher (p < .001) in the above-mentioned group. Likewise, cardiopulmonary bypass time (p = .018), aortic cross-clamp time (p = .008) and average operation time (p = .009) were significantly longer in the AVR + PH group. Furthermore, the in-hospital survival rate was significantly higher (p = .044) in the AVR group compared to the AVR + PH group. Moreover, the dialysis rate was significantly higher (p < .001) postoperatively in patients who suffered PH compared to the patients without PH undergoing AVR.ConclusionIn our study, patients with severe PH and severe symptomatic AS who underwent surgical aortic valve replacement showed adverse short-term outcomes compared to patients without PH.

cardiac & cardiovascular systems,peripheral vascular disease
Sex-Specific Differences in Upstream Cardiac Damage in Patients With Aortic Stenosis Undergoing TAVR

Masaaki Nakase,Daijiro Tomii,Annette Maznyczka,Daryoush Samim,Jonas Lanz,Fabien Praz,Stefan Stortecky,David Reineke,Stephan Windecker,Thomas Pilgrim

DOI: https://doi.org/10.1016/j.jcin.2024.03.031

IF: 11.075

2024-05-29

JACC Cardiovascular Interventions

Abstract:Background Cardiac damage caused by aortic stenosis (AS) can be categorized into stages, which are associated with a progressively increasing risk of death after transcatheter aortic valve replacement (TAVR). Objectives The authors investigated sex-related differences in cardiac damage among patients with symptomatic AS and the prognostic value of cardiac damage classification in women and men undergoing TAVR. Methods In a prospective registry, pre-TAVR echocardiograms were used to categorize patients into 5 stages of cardiac damage caused by AS. Differences in the extent of cardiac damage were compared according to sex, and its implications on clinical outcomes after TAVR were explored. Results Among 2,026 patients undergoing TAVR between August 2007 and June 2022 (995 [49.1%] women and 1,031 [50.9%] men), we observed sex-specific differences in the pattern of cardiac damage (women vs men; stage 0: 2.6% vs 3.1%, stage 1: 13.4% vs 10.1%, stage 2: 37.1% vs 39.5%, stage 3: 27.5% vs 15.6%, and stage 4: 19.4% vs 31.7%). There was a stepwise increase in 5-year all-cause mortality according to stage in women (HR adjusted : 1.43; 95% CI: 1.28-1.60, for linear trend) and men (HR adjusted : 1.26; 95% CI: 1.14-1.38, for linear trend). Female sex was associated with a lower 5-year mortality in early stages (stage 0, 1, or 2) but not in advanced stages (stage 3 or 4). Conclusions The pattern of cardiac damage secondary to AS differed by sex. In early stages of cardiac damage, women had a lower 5-year mortality than men, whereas in more advanced stages, mortality was comparable between sexes. (SwissTAVI Registry; NCT01368250 )

cardiac & cardiovascular systems

[State and perspectives of training of highly qualified surgeons (heads of departments)].

[Noncompliance relevant variables in patients with onychomycosis].

The ideological survey.

Impact of Early Changes in Cardiac Damage Following Transcatheter Aortic Valve Implantation.

The impact of extra-valvular cardiac damage on mid-term clinical outcome following transcatheter aortic valve replacement in patients with severe aortic stenosis

891 EARLY EVOLUTION OF CARDIAC DAMAGE STAGING FOLLOWING TRANSCATHETER AORTIC VALVE REPLACEMENT: PREVALENCE, CLINICAL PATTERNS AND PROGNOSTIC SIGNIFICANCE

Early evolution of cardiac damage staging following transcatheter aortic valve replacement: prevalence, clinical patterns and prognostic significance

Extent of cardiac damage and hospitalization burden in patients undergoing transcatheter aortic valve replacement

Extent of Cardiac Damage and Mortality in Patients Undergoing Transcatheter Aortic Valve Implantation

The Impact of Severe Ventricular Remodeling on Quality-of-Life Outcomes after Transcatheter Aortic Valve Replacement

Paravalvular regurgitation after transcatheter aortic valve replacement in intermediate-risk patients: a pooled PARTNER 2 study

Patient-Prosthesis Mismatch After Surgical Aortic Valve Replacement: Analysis of the PARTNER Trials

Outcome of aortic stenosis according to invasive cardiac damage staging after transcatheter aortic valve replacement

Outcomes of SAPIEN 3 Transcatheter Aortic Valve Replacement Compared With Surgical Valve Replacement in Intermediate-Risk Patients

Quality of Life 5 Years Following Transfemoral TAVR or SAVR in Intermediate Risk Patients

[A case of mild pulmonary tuberculosis complicated with the syndrome of inappropriate antidiuretic hormone secretion which caused impaired consciousness].

Effect of aortic valve replacement on myocardial perfusion and exercise capacity in patients with severe aortic stenosis

Association between trajectories in cardiac damage and clinical outcomes after transcatheter aortic valve replacement

Impact of age on health status after TAVI or SAVR in low risk patients with severe aortic stenosis: results from the PARTNER 3 Trial

Impact of pulmonary hypertension on short-term outcomes in patients undergoing surgical aortic valve replacement for severe aortic valve stenosis

Sex-Specific Differences in Upstream Cardiac Damage in Patients With Aortic Stenosis Undergoing TAVR